An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer

Panitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor. Results from the primary analysis of a phase 3, randomized, controlled study showed a statistically significant improvement in progression-free survival for patients receiving panitumumab; however, ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Poulin-Costello, Melanie, Azoulay, Laurent, Van Cutsem, Eric, Peeters, Marc, Siena, Salvatore, Wolf, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669517/
https://www.ncbi.nlm.nih.gov/pubmed/23625191
http://dx.doi.org/10.1007/s11523-013-0271-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669517/
https://www.ncbi.nlm.nih.gov/pubmed/23625191
http://dx.doi.org/10.1007/s11523-013-0271-z

Ejemplares similares